Podium to Practice: Chicago 2025 – Melanoma: RELATIVITY-098

Podium to Practice: Chicago 2025 – Melanoma: RELATIVITY-098

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Vanessa Bernstein

Icon Chair Speaker

Speakers

Dr. Omid Hamid

Dr. Elaine McWhirter

Studies / Trials Discussed

LBA9500 – Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.

Studies/trials discussed:

LBA9500 – Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.
Tagged